Wire · operational-macro
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
Bio-Techne shareholders have approved the acquisition by Merck KGaA, Darmstadt, Germany, with the transaction expected to close by late 2026 or early 2027 pending regulatory approvals. This merger will combine their life sciences portfolios, covering discovery to clinical decision making.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Life sciences founders in biotech should anticipate shifted competitive and partnership landscapes as Merck's acquisition will consolidate resources and market reach, potentially opening acquisition or collaboration opportunities for suppliers or niche innovators displaced by integration.
◆ Coverage
2 sources · 23 Sep 2026
◆ Related on Wire
◆ Topics